Bora Pharmaceuticals Announces Unveiling of New Multi-Purpose Small Molecule Site in Zhongli, Taiwan
Taipei, Taiwan (January 6, 2025) – Bora Pharmaceuticals Co., Ltd. (“Bora,” TWSE: 6472), a global cGMP contract development and manufacturing organization (CDMO), is pleased to announce the grand unveiling of its new small molecule dose form facility in Zhongli, Taiwan. This represents another key milestone in Bora’s commitment to delivering exceptional CDMO services to its clients.
The newest Bora site is designed to provide a comprehensive range of dose form manufacturing services, including complex tablets and capsules, and has unique capabilities which include segregated areas for potent and hormonal products.
“We are excited to bring the know-how of our Zhongli team and such a strong site into the Bora CDMO network,” said J.D. Mowery, President of the CDMO Division at Bora Pharmaceuticals. “Leveraging the Bora culture, this facility will complement our extensive network in Taiwan and North America to serve our partners globally.”
For more information about Bora Pharmaceuticals, visit www.boracdmo.com.
About Bora
Bora Pharmaceuticals is a premier international contract development and manufacturing organization (CDMO) specializing in formulation development, clinical and commercial manufacturing, and packaging of complex oral solid dose, liquid, semi-solid, biologics, and sterile injectable pharmaceutical products. From our world-class sites in North America and Asia, we deliver drug products with unparalleled quality to more than 100 markets around the world.
